For example, the application of peptide antagonists of the melanocortin 5 receptor can relieve tumor immune suppression caused by α-melanocyte-stimulating hormone signaling and enhance the efficacy of immune therapies targeting the PD-1 pathway.226 The administration of glucocorticoids can modulate T-cell responses and maintain their survival, thereby augmenting the antitumor immune response.495 Endocrine therapies, while effective in hormone-sensitive cancers, often fail to address the systemic metabolic changes induced by dormant tumor cells. Here, MC5R is linked to neoplasm.